Diamond Clinic Sp. z o.o.

The trials here

What the 39 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)17 trials
• Asthma6 trials
• COPD4 trials
• Vitiligo3 trials
• Alzheimer disease2 trials
• Obesity2 trials
• Psoriasis2 trials
• Alopecia areata1 trial
• Depression1 trial
• Hidradenitis suppurativa1 trial
• High blood pressure1 trial
• Type 2 diabetes1 trial

Phase

• Phase 323 trials
• Phase 212 trials
• Phase 2/32 trials
• Phase 42 trials

Status

• Completed19 trials
• Active, not recruiting12 trials
• Recruiting6 trials
• Not yet recruiting1 trial
• Suspended1 trial

Lead sponsor

• Eli Lilly and Company9 trials
• Chiesi Farmaceutici S.p.A.5 trials
• Sanofi4 trials
• Incyte Corporation3 trials
• Amgen Inc.2 trials
• and 15 more

Running trials

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Eli Lilly and Company· Source

• Recruiting

  BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])

  NCT07666490· Phase 4· Chiesi Farmaceutici S.p.A.· Source

• Active, not recruiting

  AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  NCT07400107· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

  NCT07533006· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo

  NCT07533019· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma

  2025-522640-41-00· Phase 2· Eli Lilly & Co.· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Active, not recruiting

  A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

  NCT07277660· Phase 2· UCB Biopharma SRL· Source

• Active, not recruiting

  A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

  NCT07217015· Phase 2· Kymera Therapeutics, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

  NCT06804811· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

  NCT06832618· Phase 3· Incyte Corporation· Source

• Recruiting

  Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

  NCT06855498· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

  NCT06572228· Phase 4· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06407934· Phase 3· Sanofi· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

  NCT06220604· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

  NCT06136741· Phase 2· Nektar Therapeutics· Source

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

  NCT05508789· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

  NCT05492578· Phase 2/3· Sanofi· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma2 recruiting
• Vitiligo2 recruiting
• Alopecia areata1 recruiting
• COPD1 recruiting
• Depression1 recruiting
• Hidradenitis suppurativa1 recruiting

Closed trials

• Active, not recruiting

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

  NCT07035093· Phase 3· Eli Lilly and Company· Source

• Completed

  Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis

  2023-503522-40-01· Phase 2· Anaptysbio Inc.· Source

• Completed

  Long-term safety and efficacy evaluation of subcutaneous amlitelimab in adult participants with moderate to severe asthma who completed treatment period of previous amlitelimab asthma clinical study

  NCT06033833· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

  NCT06264674· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06130566· Phase 3· Sanofi· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Completed

  A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

  2022-502888-38-00· Phase 2· Eli Lilly & Co.· Source

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source

• Completed

  Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis

  NCT05916365· Phase 3· Almirall, S.A.· Source

• Completed

  Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO)

  2022-501586-50-00· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Eli Lilly and Company· Source

• Completed

  Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

  NCT05421598· Phase 2· Sanofi· Source

• Completed

  A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD

  NCT04320342· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy

  NCT04636814· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

  NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion in Pediatric Subjects with Moderate to Severe Plaque Psoriasis

  2024-520057-20-00· Phase 2· Bausch Health Americas Inc.· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Completed

  Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

  NCT03989206· Phase 3· Galderma R&D· Source

• Completed

  A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

  NCT03952559· Phase 3· Eli Lilly and Company· Source